Humanization of Murine Neutralizing Antibodies against Human Herpesvirus 6B.
human herpesvirus 6B
humanized antibody
neutralizing antibody
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
15 05 2019
15 05 2019
Historique:
received:
18
12
2018
accepted:
26
02
2019
pubmed:
8
3
2019
medline:
3
3
2020
entrez:
8
3
2019
Statut:
epublish
Résumé
Exanthem subitum is a common childhood illness caused by primary infection with human herpesvirus 6B (HHV-6B). It is occasionally complicated by febrile seizures and even encephalitis. HHV-6B reactivation also causes encephalitis, especially after allogeneic hematopoietic stem cell transplantation. However, no adequate antiviral treatment for HHV-6B has yet been established. Mouse-derived monoclonal antibodies (MAbs) against the HHV-6B envelope glycoprotein complex gH/gL/gQ1/gQ2 have been shown to neutralize the viral infection. These antibodies have the potential to become antiviral agents against HHV-6B despite their inherent immunogenicity to the human immune system. Humanization of MAbs derived from other species is one of the proven solutions to such a dilemma. In this study, we constructed chimeric forms of two neutralizing MAbs against HHV-6B to make humanized antibodies. Both showed neutralizing activities equivalent to those of their original forms. This is the first report of humanized antibodies against HHV-6B and provides a basis for the further development of HHV-6B-specific antivirals.
Identifiants
pubmed: 30842329
pii: JVI.02270-18
doi: 10.1128/JVI.02270-18
pmc: PMC6498045
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Antiviral Agents
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
J Virol. 2003 Feb;77(4):2452-8
pubmed: 12551983
Adv Exp Med Biol. 2018;1045:251-270
pubmed: 29896671
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9096-9
pubmed: 23674671
Mol Immunol. 2008 Aug;45(14):3832-9
pubmed: 18614234
Virology. 1990 Jun;176(2):625-8
pubmed: 2161152
J Med Virol. 2017 Jan;89(1):161-169
pubmed: 27272972
Am J Med. 2011 Jul;124(7):588-97
pubmed: 21592453
J Virol. 2018 Feb 12;92(5):
pubmed: 29212944
Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5
pubmed: 6436822
Biol Blood Marrow Transplant. 2018 Nov;24(11):2324-2336
pubmed: 29684567
J Virol. 2014 Sep;88(18):10875-82
pubmed: 25008928
Mediterr J Hematol Infect Dis. 2018 May 01;10(1):e2018035
pubmed: 29755712
J Clin Microbiol. 1989 Oct;27(10):2204-7
pubmed: 2555389
Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220-4
pubmed: 2726771
Arch Virol. 1992;123(3-4):425-49
pubmed: 1562239
Lancet. 1988 May 14;1(8594):1065-7
pubmed: 2896909
Virology. 2010 Sep 30;405(2):280-8
pubmed: 20598727
Clin Microbiol Rev. 2015 Apr;28(2):313-35
pubmed: 25762531
J Virol. 2005 Oct;79(20):13037-46
pubmed: 16189006
J Gen Virol. 2002 Apr;83(Pt 4):847-854
pubmed: 11907335
Clin Infect Dis. 2013 Sep;57(5):671-81
pubmed: 23723198
J Exp Med. 1979 Jun 1;149(6):1299-313
pubmed: 109566
Cell Microbiol. 2009 Jul;11(7):1001-6
pubmed: 19290911
Curr Opin Virol. 2017 Jun;24:97-104
pubmed: 28538165
J Virol. 2004 Aug;78(15):7969-83
pubmed: 15254169
J Neurovirol. 2017 Feb;23(1):1-19
pubmed: 27538995
Clin Microbiol Rev. 1997 Jul;10(3):521-67
pubmed: 9227865
Bone Marrow Transplant. 2015 Aug;50(8):1030-6
pubmed: 25915811
J Virol. 2011 Dec;85(24):12962-71
pubmed: 21957287
Biol Blood Marrow Transplant. 2012 Nov;18(11):1638-48
pubmed: 22564265
J Immunol Methods. 2000 Jan 13;233(1-2):167-77
pubmed: 10648866